Biohaven Ltd. Files 8-K: Corporate and Financial Update

TL;DR

Biohaven Ltd. filed an 8-K on 3/12/24 for corporate updates.

AI Summary

Biohaven Ltd. filed an 8-K on March 12, 2024, to report other events and financial statements. The filing details the company's corporate structure and addresses, noting its incorporation in the British Virgin Islands and principal executive offices located at 215 Church Street, New Haven, Connecticut.

Why It Matters

This filing provides essential corporate information and updates for Biohaven Ltd., which is crucial for investors and stakeholders to understand the company's current structure and reporting status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

• Biohaven Ltd. (company) — Registrant
• March 12, 2024 (date) — Date of Report
• British Virgin Islands (location) — Jurisdiction of Incorporation
• 215 Church Street, New Haven, Connecticut (location) — Principal Executive Offices
• 001-41477 (other) — Commission File Number

FAQ

Filing Documents

• bhvn-20240312.htm (8-K) — 23KB
• exhibit51maplesopinionandc.htm (EX-5.1) — 31KB
• image_0.jpg (GRAPHIC) — 82KB
• 0001935979-24-000020.txt ( ) — 277KB
• bhvn-20240312.xsd (EX-101.SCH) — 2KB
• bhvn-20240312_lab.xml (EX-101.LAB) — 21KB
• bhvn-20240312_pre.xml (EX-101.PRE) — 12KB
• bhvn-20240312_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On March 12, 2024, Biohaven Ltd. (the "Company") filed a prospectus supplement to its Registration Statement on Form S-3 (No. 333-274822) (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "Commission"), under the Securities Act of 1933, as amended, with respect to the resale by the selling shareholders named therein of 45,883 common shares, no par value, of the Company that were issued by the Company to such selling shareholders as share consideration in connection with the transactions and business arrangements described therein. In connection with the filing of the prospectus supplement, the Company is filing a legal opinion as Exhibit No. 5.1 to this Current Report on Form 8-K, which is incorporated by reference into the Registration Statement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 5.1 Opinion of Maples & Calder . 23.1 Consent of Maples & Calder (included in Exhibit 5.1). 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 12, 2024 Biohaven Ltd. By: /s/ Matthew Buten Matthew Buten Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR